bendamustine accord
accord healthcare b.v. - bendamustino hidrochloridas - milteliai infuzinio tirpalo koncentratui - 2,5 mg/ml - bendamustine
bendamustine kabi
fresenius kabi polska sp.z.o.o. - bendamustino hidrochloridas - milteliai infuzinio tirpalo koncentratui - 2,5 mg/ml - bendamustine
bendamustine medac
medac gesellschaft für klinische spezialpräparate mbh - bendamustino hidrochloridas - milteliai infuzinio tirpalo koncentratui - 2,5 mg/ml - bendamustine
bleomycin medac
medac gesellschaft für klinische spezialpräparate mbh - bleomicinas - milteliai injekciniam tirpalui - 15000 tv - bleomycin
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antinavikiniai vaistai - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
bendamustine sandoz
sandoz d.d. - bendamustino hidrochloridas - milteliai infuzinio tirpalo koncentratui - 2,5 mg/ml - bendamustine
carmustine zentiva [carmustine tillomed]
zentiva k.s. - karmustinas - milteliai ir tirpiklis infuzinio tirpalo koncentratui - 100 mg - carmustine
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antinavikiniai vaistai - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
nodexon
norameda, uab - deksametazonas - tabletės - 4 mg - dexamethasone
nodexon
norameda, uab - deksametazonas - tabletės - 8 mg - dexamethasone